Download PDF
Thromb Haemost 2010; 104(02): 194-195
DOI: 10.1160/TH09-12-0839
Editorial Focus
Schattauer GmbH

Ischaemic preconditioning and stem cell mobilisation

Qizhou Lian
1   Cardiology Division, Department of Medicine, the University of Hong Kong, Hong Kong SAR, China
2   Research Centre of Heart, Brain, Hormone, and Healthy Aging, the University of Hong Kong, Hong Kong SAR, China
,
Hung-Fat Tse
1   Cardiology Division, Department of Medicine, the University of Hong Kong, Hong Kong SAR, China
2   Research Centre of Heart, Brain, Hormone, and Healthy Aging, the University of Hong Kong, Hong Kong SAR, China
› Author Affiliations Financial support: This work was supported by grants from Seed Funding for Basic Research (#10208618 to Q Lian) and Small Project Funding (#10400639, to Q Lian); and HKU Strategic Research Theme on Healthy Ageing (to Q Lian and HF Tse) from the University of Hong Kong.
Further Information

Publication History

Received: 15 December 2009

Accepted: 15 April 2009

Publication Date:
24 November 2017 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia – a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
    CrossrefPubMedGoogle Scholar
  • 2 Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007; 12: 181-188.
    CrossrefPubMedGoogle Scholar
  • 3 Ii M, Nishimura H, Iwakura A. et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported„ nitric oxide synthase activity. Circulation 2005; 111: 1114-1120.
    CrossrefPubMedGoogle Scholar
  • 4 Kamota T, Li TS, Morikage N. et al. Ischemic preconditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol 2009; 53: 1814-1822.
    CrossrefPubMedGoogle Scholar
  • 5 Gyongyosi M, Posa A, Pavo N. et al. Differential effect of ischaemic preconditioning on mobilisation and recruitment of hematopoietic and mesenchymal stem cells in porcine myocardial ischaemic-reperfusion. Thromb Haemost 2010; 103: 376-384.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y, Han ZC. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007; 98: 1335-1342.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Torella D, Ellison GM, Mendez-Ferrer S. et al. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006; 03 (Suppl. 01) S8-13.
    CrossrefPubMedGoogle Scholar
  • 8 Egan CG, Caporali F, Huqi AF. et al. Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: kinetics following percutaneous coronary intervention and association with clinical characteristics. Thromb Hae-most 2009; 101: 1138-1146.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Timmers L, Lim SK, Arslan F. et al. Reduction of myocardial infarct size by human mesenchymalstem cell conditioned medium. Stem Cell Res 2007; 01: 129-137.
    PubMedGoogle Scholar
  • 10 Gnecchi M, He H, Liang OD. et al. Paracrine action accounts for marked protection of ischemic heart by Aktmodified mesenchymal stem cells. Nat Med 2005; 11: 367-368.
    CrossrefPubMedGoogle Scholar
  • 11 Tse HF, Zhu SG, Zhang OY. et al. Paracrine effects of direct intramyocardial implantation of bone marrow mononuclear cells to enhance neovascularization in chronic ischernic myocardium. Eur J Heart Fail 2007; 09: 747-753.
    CrossrefPubMedGoogle Scholar
  • 12 Menasche P. Stem cells for clinical use in cardiovascular medicine. Thromb Haemost 2005; 94: 697-701.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Tse HF, Thambar S, Kwong YL. et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007; 28: 2998-3005.
    CrossrefPubMedGoogle Scholar
  • 14 Niagara MI, Haider HK, Jiang SJ. et al. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100: 545-555.
    CrossrefPubMedGoogle Scholar
  • 15 Tang YL, Zhu W, Cheng M. et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009; 104: 1209-1216.
    CrossrefPubMedGoogle Scholar